Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 1—January 2019
Research

Risk Factors for Elizabethkingia Acquisition and Clinical Characteristics of Patients, South Korea

Min Hyuk Choi, Myungsook Kim, Su Jin Jeong, Jun Yong Choi1Comments to Author , In-Yong Lee, Tai-Soon Yong, Dongeun Yong, Seok Hoon Jeong, and Kyungwon Lee1Comments to Author 
Author affiliations: National Health Insurance Service Ilsan Hospital, Goyang, South Korea (M.H. Choi); Yonsei University College of Medicine, Seoul, South Korea (M.H. Choi, M. Kim, S.J. Jeong, J.Y. Choi, I.-Y. Lee, T.-S. Yong, D. Yong, S.H. Jeong, K. Lee)

Main Article

Table 4

Results of univariate and multivariate analysis using conditional logistic regression of risk factors for the acquisition of Elizabethkingia species at a tertiary teaching hospital after propensity score matching, Seoul, South Korea*

Variable Univariate analysis Multivariate analysis†
OR (95% CI)
 p value
 OR (95% CI)
 p value
Ward
Ward A Reference
Ward B 0.87 (0.41–1.79) 0.70
Intensive care unit 1
 0.69 (0.18–2.22)
 0.56
Period of admission
2016 Jan–Mar Reference
2016 Apr–Jun 8.03 (0.79–81.98) 0.08
2016 Jul–Sep 8.87 (0.74–105.84) 0.08
2016 Oct–Dec 10.62 (0.64–176.77) 0.10
2017 Jan–Mar 8.87 (0.97–81.16) 0.05
2017 Apr–Jun
 8.34 (0.71–98.76)
 0.09
Median stay in 3 wards, d 1.01 (0.99–1.02) 0.25
Age, y 1.00 (0.98–1.02) 0.87
Male sex 1.06 (0.55–2.02) 0.87
Charlson comorbidity index
 0.97 (0.85–1.12)
 0.69
Comorbidities‡
Solid organ tumor 0.48 (0.21–1.08) 0.08
Diabetes mellitus 0.89 (0.34–2.31) 0.81
Chronic pulmonary disease 1.85 (0.55–6.28) 0.32
Chronic kidney disease 1.52 (0.60–3.85) 0.38
Hematologic malignancy 1.00 (0.25–4.00) 0.99
Dementia 0.57 (0.12–2.77) 0.49
Connective tissue disease 0.80 (0.21–3.05) 0.75
Mild liver disease 1.00 (0.10–9.61) 0.99
Steroid use 1.55 (0.62–3.89) 0.35
Mechanical ventilation
 64.54 (8.76–475.30)
 <0.01
50.44 (6.74–377.48)
 <0.01
Antimicrobial exposure
Penicillin§ 0.32 (0.07–1.54) 0.16
1st-generation cephalosporin 0.29 (0.03–2.88) 0.29
2nd-generation cephalosporin 3.00 (0.42–21.30) 0.27
3rd-generation cephalosporin 0.97 (0.46–2.01) 0.93
4th-generation cephalosporin NA
Aminoglycoside 3.18 (1.21–8.31) 0.02 2.30 (0.62–8.47) 0.21
Glycopeptide 3.96 (1.82–8.63) <0.01 1.72 (0.50–5.86) 0.39
Linezolid 8.84 (0.97–80.69) 0.05
Carbapenem 4.16 (1.99–8.72) <0.01 1.63 (0.55–4.85) 0.38
Tetracycline 1.65 (0.42–6.43) 0.47
Trimethoprim/sulfamethoxazole 2.11 (0.90–4.91) 0.09
Lincosamide 6.00 (0.54–66.17) 0.14
Macrolide 0.75 (0.08–6.71) 0.80
Fluoroquinolone 3.42 (1.70–6.87) <0.01 2.01 (0.71–5.69) 0.19
Other 2.09 (0.48–9.03) 0.33

*OR, odds ratio; NA, not available.
†Only variables with p<0.05 in the univariate model were included in the multivariate model.
‡May be multiple.
§Includes aminopenicillin, β-lactam/β-lactamase inhibitor.

Main Article

1These authors contributed equally to this article.

Page created: December 17, 2018
Page updated: December 17, 2018
Page reviewed: December 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external